

**FORMATO EUROPEO  
PER IL CURRICULUM  
VITAE**



**INFORMAZIONI PERSONALI**

Nome/Cognome

Indirizzo

Telefono Ufficio

Fax Ufficio

E-mail

CODICE FISCALE

Nazionalità

Data di nascita

Luogo di nascita

ORCID ID

**SERGIO ABRIGNANI**

UNIVERSITÀ DEGLI STUDI DI MILANO - UNIMI

INGM ISTITUTO NAZIONALE GENETICA MOLECOLARE "ROMEO ED ENRICA INVERNIZZI"

PADIGLIONE INVERNIZZI - VIA FRANCESCO SFORZA, 35 – 20122 MILANO

02 0066 0328

02 0066 0216

[abrignani@ingm.org](mailto:abrignani@ingm.org) ; [sergio.abrignani@unimi.it](mailto:sergio.abrignani@unimi.it)

BRGSRG58H03E974U

Italiana

03 GIUGNO 1958

MARSALA (TP)

0000-0002-0794-3285

**ESPERIENZA LAVORATIVA**

• Date (da - a)

• Nome e indirizzo del datore di lavoro

• Tipo di azienda o settore

• Tipo di impiego

• Date (da – a)

• Nome e indirizzo del datore di lavoro

• Tipo di azienda o settore

• Tipo di impiego

• Date (da – a)

• Nome e indirizzo del datore di lavoro

• Tipo di azienda o settore

• Tipo di impiego

• Date (da – a)

• Nome e indirizzo del datore di lavoro

• Tipo di azienda o settore

• Tipo di impiego

• Date (da – a)

• Nome e indirizzo del datore di lavoro

• Tipo di azienda o settore

• Tipo di impiego

01 Giugno 2015

**Università degli Studi di Milano** – Via Festa del Perdono, 7 – 20122 Milano

Università

Professore ordinario di Patologia Generale - Dipartimento di Scienze Cliniche e di Comunità (DISCCO)

01 Gennaio 2006

**FONDAZIONE INGM** Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi"

Centro di Ricerca Biomedica finalizzato alla scoperta e allo sviluppo iniziale di nuovi mezzi diagnostici, nuove terapie e vaccini.

Direttore Scientifico

1999-2005

Chiron Corporation, Emeryville (CA), USA

Biotecnologia

Vice Presidente, Dipartimento di ricerca e sviluppo

1994 – 2000

Università di Siena

Scuola di specializzazione in Gastroenterologia, Facoltà di Medicina

Professore a contratto

Aprile 1993 – 1999

Centro Ricerche Chiron - Siena

Biotecnologia

Direttore del Dipartimento di Immunologia e Virologia

- Date (da – a)
- Nome e indirizzo del datore di lavoro
  - Tipo di azienda o settore
  - Tipo di impiego

1990 – Marzo 1992  
Ciba-Geigy, Basilea, Svizzera

Responsabile del Laboratorio Vaccini presso il Dipartimento di Allergia/Immunologia

- Date (da – a)
- Nome e indirizzo del datore di lavoro
  - Tipo di azienda o settore
  - Tipo di impiego

1988 – 1989  
Ciba-Geigy, Basilea, Svizzera

Ricercatore presso il Dipartimento di Allergia/Immunologia

- Date (da – a)
- Nome e indirizzo del datore di lavoro
  - Tipo di azienda o settore
  - Tipo di impiego

1986 – 1987  
Sandoz, Basilea, Svizzera

Ricercatore presso il Dipartimento di Ricerca Preclinica

- Date (da – a)
- Nome e indirizzo del datore di lavoro
  - Tipo di azienda o settore
  - Tipo di impiego

1983 – 1985  
Istituto di Patologia Generale, Facoltà di Medicina, Università di Palermo

Assistente Medico

#### **PREMI E RICONOSCIMENTI**

- Date (da–a)

2011-2016

ERC Advanced Grant

“Lymphocyte microRNAs in health and disease: Understanding lymphocyte functions through the identification of microRNA target genes and exploiting serum microRNA signatures to monitor immune responses”.

- Date (da–a)

2004

Medaglia d'oro al merito della Salute Pubblica, per i suoi studi sul virus dell'epatite C

#### **ISTRUZIONE E FORMAZIONE**

- Date (da – a)
- Nome e tipo di istituto di istruzione o formazione
  - Principali materie / abilità professionali oggetto dello studio
    - Qualifica conseguita
  - Livello nella classificazione nazionale (se pertinente)

1986

Facoltà di Medicina dell'Università di Palermo

Specializzazione in Patologia Generale, votazione 70/70 con lode

- Date (da – a)
- Nome e tipo di istituto di istruzione o formazione
  - Principali materie / abilità professionali oggetto dello studio
  - Qualifica conseguita
- Livello nella classificazione nazionale (se pertinente)

1982  
Facoltà di Medicina dell'Università di Padova

Laurea in medicina, votazione 110/110 con lode

- Date (da – a)
- Nome e tipo di istituto di istruzione o formazione
  - Principali materie / abilità professionali oggetto dello studio
  - Qualifica conseguita
- Livello nella classificazione nazionale (se pertinente)

1976  
Liceo Classico "Giovanni XXIII", Marsala (TP)

Maturità Classica

## CAPACITÀ E COMPETENZE

### PERSONALI

*Acquisite nel corso della vita e della carriera ma non necessariamente riconosciute da certificati e diplomi ufficiali.*

#### PRIMA LINGUA

#### ITALIANO

#### ALTRE LINGUE

Autovalutazione  
Livello europeo (\*)

#### Comprensione

#### Parlato

#### Scritto

Ascolto

Lettura

Interazione

Produzione orale

#### Inglese

C2 Utente avanzato C2 Utente avanzato C2 Utente avanzato C2 Utente avanzato C2 Utente avanzato

#### Tedesco

B1 Utente autonomo B1 Utente autonomo B1 Utente autonomo B1 Utente autonomo B1 Utente autonomo

(\*) Quadro comune europeo di riferimento per le lingue

**ALTRE ATTIVITÀ  
PROFESSIONALI**

Not for profit institutions

2015	Università La Sapienza, Roma	Membro del Consiglio di Amministrazione
2006 –	Fondazione INGM, Milano	Membro del Consiglio di Amministrazione
2015 –	Sclavo Vaccine Associations, Siena	Membro del Consiglio di Amministrazione
2017 –	Fondazione Carlo Erba, Milano	Membro del Consiglio di Amministrazione

Companies

2015 –	Impact Lab Srl, Milano	Membro del Consiglio di Amministrazione
2018 –	Check mAb Srl, Milano	Membro del Consiglio di Amministrazione

-----

Scientific Advisory Board membership

2013 –	Fondazione Regionale per la Ricerca Biomedica – FRRB, Milano	Membro del Comitato Tecnico Scientifico
2016 –	Toscana Life Sciences, Siena	Membro del Comitato Tecnico Scientifico
2018-	Ministero della Salute, Roma	Membro del Comitato Tecnico Sanitario

## ULTERIORI INFORMAZIONI

“Reviewer” di articoli sulle seguenti riviste scientifiche:

European Journal of Immunology  
EMBO Journal  
Frontiers in Immunology  
Hepatology  
Immunity  
International Immunology  
Journal of Clinical Investigation  
Journal of Hepatology  
Journal of Immunology  
Nature  
Nature Immunology  
Nature Medicine  
Science

### Pubblicazioni

H index secondo Google Scholar: **63**

Totale citazioni secondo Google Scholar: 14486

	Tutte	Dal 2013
Citazioni	14486	4755
H index	63	38

**(\*\*)** indica che Sergio Abrignani è corresponding author

### **2018**

1. Alfen JS, Larghi P, Facciotti F, Gagliani N, Bosotti R, Paroni M, Maglie S, Guarini P, Vasco CM, Ranzani V, Frusteri C, Iseppon A, Moro M, Crosti MC, Gatti S, Pagani M, Caprioli F, **Abrignani S**, Flavell RA, Geginat J. “Intestinal IFN- $\gamma$ -producing Tr1-cells co-express CCR5 and PD-1, and down regulate IL-10 in the inflamed gut of IBD patients”. J Allergy Clin Immunol. 2018 Jan 21. pii: S0091-6749(18)30078-2. doi: 10.1016/j.jaci.2017.12.984. [Epub ahead of print]

### **2017**

2. **(\*\*)** Ripamonti A, Provasi E, Lorenzo M, De Simone M, Ranzani V, Vangelisti S, Curti S, Bonnal RJP, Torretta S, Geginat, Tossetti G, Pagani M, **Abrignani S**. “Repression of miR-31 by BCL6 stabilizes the helper function of human follicular helper T cells”. PNAS 2017; 114(48):12797-12802.
3. Cano-Rodriguez D, Campagnoli S, Grandi A, Parri M, Camilli E, Song C, Jin B, Lacombe A, Pierleoni A, Bombaci M, Cordiglieri C, Ruiters MH, Viale G, Terracciano L, Sarmientos P, **Abrignani S**, Grandi G, Pileri P, Rots MG, Grifantini R. “TCTN2: a novel tumor marker with oncogenic properties”. Oncotarget. 2017

4. Ferlito C, Barnaba V, **Abrignani S**, Bombaci M, Sette A, Sidney J, Biselli R, Tomao E, Cattaruzza MS, Germano V, Biondo MI, Salerno G, Lulli P, Caporuscio S, Diamanti AP, Falco M, Biselli V, Cardelli P, Autore A, Lucertini E, Pompeo De Cesare DP, Peragallo MS, Lista F, Martire C, Salemi S, Nisini R, D'Amelio R. „Lack of evidence for post-vaccine onset of autoimmune/lymphoproliferative disorders, during a nine-month follow-up in multiply vaccinated Italian military personnel“. Clin Immunol.2017 Aug;181:60-66.
5. Geginat J, Paroni M, Pagani M, Galimberti D, De Francesco R, Scarpini E, **Abrignani S**. „The Enigmatic Role of Viruses in Multiple Sclerosis: Molecular Mimicry or Disturbed Immune Surveillance?“ Trends Immunol. 2017 Jul;38(7):498-512.
6. Penatti A, Facciotti F, De Matteis R, Larghi P, Paroni M, Murgo A, De Lucia O, Pagani M, Pierannunzii L, Truzzi M, Ioan-Facsinay A, **Abrignani S**, Geginat J, Meroni PL. „Differences in serum and synovial CD4+ T cells and cytokine profiles to stratify patients with inflammatory osteoarthritis and rheumatoid arthritis“. Arthritis Res Ther. 2017 May 19;19(1):103.
7. Paroni M, Maltese V, De Simone M, Ranzani V, Larghi P, Fenoglio C, Pietroboni AM, De Riz MA, Crosti MC, Maglie S, Moro M, Caprioli F, Rossi R, Rossetti G, Galimberti D, Pagani M, Scarpini E, **Abrignani S**, Geginat J. „Recognition of viral and self-antigens by TH1 and TH1/TH17 central memory cells in patients with multiple sclerosis reveals distinct roles in immune surveillance and relapses“. J Allergy Clin Immunol. 2017 Sep;140(3):797-808.
8. Mazzara S, Rossi RL, Grifantini R, Donizetti S, **Abrignani S**, Bombaci M. „CombiROC: an interactive web tool for selecting accurate marker combinations of omics data“. Sci Rep. 2017 Mar 30;7:45477.
9. Ranzani V, Arrigoni A, Rossetti G, Panzeri I, **Abrignani S**, Bonnal RJ, Pagani M. „Next-Generation Sequencing Analysis of Long Noncoding RNAs in CD4+ T Cell Differentiation“. Methods Mol Biol. 2017;1514:173-185.
10. (\*\*) Torri A, Carpi D, Bulgheroni E, Crosti MC, Moro M, Guarini P, Rossi RL, Rossetti G, Di Vizio D, Hoxha M, Bollati V, Gagliani C, Tacchetti C, Paroni M, Geginat J, Corti L, Venegoni L, Berti E, Pagani M, Matarese G, **Abrignani S**, de Candia P. „Extracellular microRNA signature of human helper T cell subsets in health and autoimmunity.“ J Biol Chem. 2017 Feb 17; 292(7): 2903-2915.

## 2016

11. Fedeli M, Riba M, Garcia Manteiga JM, Tian L, Viganò V, Rossetti G, Pagani M, Xiao C, Liston A, Stupka E, Cittaro D, **Abrignani S**, Provero P, Dellabona P, Casorati G. „miR-17~92 family clusters control iNKT cell ontogenesis via modulation of TGF- $\beta$  signaling“. Proc. Natl. Acad. Sci. U S A. 2016 Dec 20;113(51):E8286-E8295.

12. (\*\*) De Simone M, Arrigoni A, Rossetti G, Guarini P, Ranzani V, Politano C1, Bonnal RJP, Provasi E, Sarnicola M, Panzeri I, Moro M, Crosti M, Mazzara S, Vaira V, Bosari S, Palleschi A, Santambrogio L, Bovo G, Zucchini N, Totis M, Gianotti L, Cesana G, Perego R, Maroni N, Pisani Ceretti A, Opocher E, De Francesco R, Geginat J, Stunnenberg HG, **Abrignani S**, Pagani M. "Transcriptional landscape of human tissue lymphocytes unveils uniqueness of tumor-infiltrating T regulatory cells" *Immunity*. 2016 Nov 15;45(5):1135-1147
13. Stunnenberg HG; International Human Epigenome Consortium, Hirst M. "The International Human Epigenome Consortium: A Blueprint for Scientific Collaboration and Discovery" *Cell*. 2016 Nov 17;167(5):1145-1149.
14. Geginat J, Paroni M, Kastirr I, Larghi P, Pagani M, **Abrignani S**. „Reverse plasticity: TGF- $\beta$  and IL-6 induce Th1-to-Th17-cell transdifferentiation in the gut". *Eur J Immunol*. 2016 Oct;46(10):2306-2310.
15. Arrigoni A, Ranzani V, Rossetti G, Panzeri I, **Abrignani S**, Bonnal RJ, Pagani M. „Analysis RNA-seq and Noncoding RNA" *Methods Mol Biol*. 2016;1480:125-35.
16. Paroni M, Magarotto A, Tartari S, Nizzoli G, Larghi P, Ercoli G, Gianelli U, Pagani M, Elli L, **Abrignani S**, Conte D, Geginat, Caprioli F. "Uncontrolled IL-17 Production by Intraepithelial Lymphocytes in a Case of non-IPEX Autoimmune Enteropathy." *Clin Transl Gastroenterol*. 2016 Jul 14;7(7):e182.
17. Nizzoli G, Larghi P, Paroni M, Crosti MC, Moro M, Neddermann P, Caprioli F, Pagani M, De Francesco R, **Abrignani S**, Geginat J. "IL-10 promotes homeostatic proliferation of human CD8+ memory T cells and, when produced by CD1c+ DCs, shapes naive CD8+ T-cell priming" *Eur J Immunol*. 2016 Jul;46(7):1622-32.
18. Geginat J, Larghi P, Paroni M, Nizzoli G, Penatti A, Pagani M, Gagliani N, Meroni P, **Abrignani S**, Flavell RA. "The light and the dark sides of Interleukin-10 in immune-mediated diseases and cancer" *Cytokine Growth Factor Rev*. 2016 Aug;30:87-93.
19. (\*\*) de Candia P, Torri A, Fedeli M, Viganò V, Carpi D, Gorletta T, Casorati G, Pagani M, Dellabona P, **Abrignani S**. "The circulating microRNome demonstrates distinct lymphocyte subset-dependent signatures". *Eur J Immunol*. 2016 Mar;46(3):725-31
20. Facciotti F, Gagliani N, Häringer B, Alfen JS, Penatti A, Maglie S, Paroni M, Iseppon A, Moro M, Crosti MC, Stölzel K, Romagnani C, Moroni G, Ingegnoli F, Torretta S, Pignataro L, Annoni A, Russo F, Pagani M, **Abrignani S**, Meroni P, Flavell R, Geginat J. "IL-10-producing forkhead box protein 3-negative regulatory T cells inhibit B-cell responses and are involved in systemic lupus erythematosus". *J Allergy Clin Immunol*. 2016 Jan;137(1):318-321.
21. Marabita F, de Candia P, Torri A, Tegnér J, **Abrignani S**, Rossi RL. "Normalization of circulating microRNA expression data obtained by quantitative real-time RT-PCR." *Brief Bioinform*. 2016 Mar;17(2):204-12.

## 2015

22. Kastirr I, Crosti MC, Maglie S, Paroni M, Steckel B, Moro M, Pagani M, **Abrignani S**, Geginat J "Signal Strength and Metabolic Requirements Control Cytokine-Induced Th17 Differentiation of Uncommitted Human T Cells" *J Immunol*. 2015 Oct 15;195(8):3617-27.
23. Panzeri I, Rossetti G, **Abrignani S**, Pagani M "Long Intergenic Non-Coding RNAs: Novel Drivers of Human Lymphocyte Differentiation". *Front Immunol*. 2015 Apr 15;6:175.
24. Geginat J, Nizzoli G, Paroni M, Maglie S, Larghi P, Pascolo S, **Abrignani S**. "Immunity to Pathogens Taught by Specialized Human Dendritic Cell Subsets". *Front Immunol*. 2015 Oct 13;6:527.
25. Sefer R, Reed SG, O'Hagan D, Malyala P, Doro U, Laera D, **Abrignani S**, Cerundolo V, Steinman L, Bertholet S. „Gaps in knowledge and prospects for research of adjuvanted vaccines“. *Vaccine*. 2015 Jun 8;33 Suppl 2:B40-3. doi: 10.1016/j.vaccine.2015.03.057.
26. Bonnal RJ, Ranzani V, Arrigoni A, Curti S, Panzeri I, Gruarin P, **Abrignani S**, Rossetti G, Pagani M. "De novo transcriptome profiling of highly purified human lymphocytes primary cells." *Sci Data*. 2015 Sep 29;2:150051.
27. Cheroni C, Donnici L, Aghemo A, Balistreri F, Bianco A, Zanoni V, Pagani M, Soffredini R, D'Ambrosio R, Rumi MG, Colombo M, **Abrignani S**, Neddermann P, De Francesco R. "Hepatitis C Virus Deletion Mutants Are Found in Individuals Chronically Infected with Genotype 1 Hepatitis C Virus in Association with Age, High Viral Load and Liver Inflammatory Activity." *PLoS One*. 2015 Sep 25;10(9):e0138546.
28. Mazzara S, Sinisi A, Cardaci A, Rossi RL, Muratori L, **Abrignani S**, Bombaci M. "Two of Them Do It Better: Novel Serum Biomarkers Improve Autoimmune Hepatitis Diagnosis". *PLoS One*. 2015 Sep 16;10(9):e0137927
29. Bonnal R JP, Rossi RL, Carpi D, Ranzani V, **Abrignani S**, Pagani M. "miRiadne: a web tool for consistent integration of miRNA nomenclature" *Nucleic Acids Res*. 2015 Jul 1;43(W1):W487-92.
30. (\*\*) Ranzani V, Rossetti G, Panzeri I, Arrigoni A, Bonnal RJP, Curti S, Provasi E, Sugliano E, De Francesco R, Geginat J, Bodega B, **Abrignani S**, Pagani M. "LincRNAs landscape in human lymphocytes highlights regulation of T cell differentiation by linc-MAF-4". *Nat Immunol*. 2015 Mar;16(3):318-25.

## 2014

31. (\*\*) Geginat J, Paroni M, Maglie S, Alfen JS, Kastirr I, Gruarin P, DeSimone M, Pagani M, **Abrignani S**. "Plasticity of human CD4 T cell subsets". *Front Immunol*.



2014, 5:630.

32. (\*\*) de Candia P, Torri A, Pagani M, **Abrignani S** "Serum microRNAs as biomarkers of human lymphocyte activation in health and disease" *Frontiers in Immunology*, 2013; 10:5-43.
33. Reghellin V, Donnici L, Fenu S, Berno V, Calabrese V, Pagani M, **Abrignani S**, Peri F, De Francesco R, Neddermann P. "NS5A inhibitors impair NS5A- PI4KIIIa complex formation and cause a decrease of PI4P and cholesterol levels in HCV-associated membranes." *Antimicrob Agents Chemother*. 2014 Dec;58(12):7128-40.
34. Kastir I, Maglie S, Paroni M, Alfen JS, Nizzoli G, Sugliano E, Crosti MC, Moro M, Steckel B, Steinfeld S, Stölzel K, Romagnani C, Botti F, Caprioli F, Pagani M, **Abrignani S**, Geginat J "IL-21 Is a Central Memory T Cell-Associated Cytokine That Inhibits the Generation of Pathogenic Th1/17 Effector Cells" *J Immunol*. 2014 Oct 1;193(7):3322-31.
35. (\*\*) Dellabona P, **Abrignani S**, Casorati G "iNKT cell help to B cells: a cooperative job between innate and adaptive immune responses". *European Journal of Immunology*, 2014; 44(8):2230-7.
36. (\*\*) Zingaretti C, De Francesco R, **Abrignani S**, "Why it is so difficult to develop an HCV preventive vaccine?". *Clinical Microbiology and Infection*, 2014 May; 20 Suppl. 5:103-9.
37. Colombatto P, Brunetto MR, Maina AM, Romagnoli V, Almasio P, Rumi MG, Ascione A, Pinzello G, Mondelli M, Muratori L, Rappuoli R, Rosa D, Houghton M, **Abrignani S**, Bonino F. "HCV E1E2-MF59 vaccine in chronic hepatitis C patients treated with PEG-IFN $\alpha$ 2a and Ribavirin: a randomized controlled trial". *J Viral Hepat*. 2014 Jul;21(7):458-65. doi: 10.1111/jvh.12163. Epub 2013 Aug 27.
38. Bottai D, Scesa G, Cigognini D, Adami R, Nicora E, **Abrignani S**, Di Giulio AM, Gorio A. "Third trimester NG2-positive amniotic fluid cells are effective in improving repair in spinal cord injury". *Exp Neurol*. 2014 Apr;254:121-33. doi: 10.1016/j.expneurol.2014.01.015. Epub 2014 Jan 29.

## 2013

39. (\*\*) de Candia P, Torri A, Gorletta T, Fedeli M, Bulgheroni E, Cheroni C, Marabita F, Crosti M, Moro M, Pariani E, Romanò L, Esposito S, Mosca F, Rossetti G, Rossi RL, Geginat J, Casorati G, Dellabona P, Pagani M, **Abrignani S**, "Intracellular Modulation, Extracellular Disposal and Serum Increase of MiR-150 Mark Lymphocyte Activation". *PLoS One*. 2013 Sep 26;8(9).
40. (\*\*) Geginat J, Paroni M, Facciotti F, Gruarin P, Kastir I, Caprioli F, Pagani M, **Abrignani S**, "The CD4-centered universe of human T cell subsets". *Semin Immunol*. 2013; 25(4):252-62.

41. Nizzoli G, Krietsch J, Weick A, Steinfeld S, Facciotti F, Gruarin P, Bianco A, Steckel B, Moro M, Crosti M, Romagnani C, Stoelzel K, Torretta S, Pignataro L, Scheibenbogen C, Neddermann P, De Francesco R, **Abrignani S**, Geginat J., "Human CD1c+ dendritic cells secrete high levels of IL-12 and potently prime cytotoxic T cell responses". *Blood*, 2013; 122(6): 932-42.
42. (\*\*) Pagani M, Rossetti G, Panzeri I, de Candia P, Bonnal RJ, Rossi RL, Geginat J, **Abrignani S**. "Role of microRNAs and long-non-coding RNAs in CD4(+) T-cell differentiation". *Immunol Rev*. 2013; 253(1):82-96.
43. Law JL, Chen C, Wong J, Hockman D, Santer DM, Frey SE, Belshe RB, Wakita T, Bukh J, Jones CT, Rice CM, **Abrignani S**, Tyrrell DL, Houghton M., "A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans". *PLoS One* 2013; 8(3):e59776.
44. Lampertico P, Viganò M, Cheroni C, Facchetti F, Invernizzi F, Valveri V, Soffredini R, **Abrignani S**, De Francesco R, Colombo M. "IL28B polymorphisms predict interferon-related HBsAg seroclearance in genotype D HBeAg-negative patients with chronic hepatitis B". *Hepatology* 2012; 57(3):890-6.
45. Delang L, Neyts J, Vliegen I, **Abrignani S**, Neddermann P, De Francesco R., "Hepatitis C virus-specific directly acting antiviral drugs". *Curr Top Microbiol . Immunol*. 2013; 369:289-320.
46. Caprioli F, Bosè F, Rossi RL, Petti L, Viganò C, Ciafardini C, Raeli L, Basilisco G, Ferrero S, Pagani M, Conte D, Altomare G, Monteleone G, **Abrignani S**, Reali E., "Reduction of CD68+ Macrophages and Decreased IL-17 Expression in Intestinal Mucosa of Patients with Inflammatory Bowel Disease Strongly Correlate With Endoscopic Response and Mucosal Healing following Infliximab Therapy". *Inflamm Bowel Dis*. 2013; 19(4):729-739.

## 2012

47. (\*\*) Zingaretti C, Arigo' M, Cardaci A, Moro M, Crosti M, Sinisi A, Sugliano E, Cheroni C, Marabita F, Nogarotto R, Bonnal RJ, Marcatili P, Marconi M, Zignego A, Muratori P, Invernizzi P, Colombatto P, Brunetto M, Bonino F, De Francesco R, Geginat J, Pagani M, Muratori L, **Abrignani S**, Bombaci M, "Identification of new autoantigens by protein array indicates a role for IL4 neutralization in Autoimmune Hepatitis". *Mol Cell Proteomics*. 2012; 11(12):1885-97.
48. (\*\*) Moro M, Crosti M, Creo P, Gallina P, Curti S, Sugliano E, Scavelli R, Cattaneo D, Canidio E, Marconi M, Rebullà P, Sarmientos P, Viale G, Pagani M, **Abrignani S**. "Identification of new hematopoietic cell subsets with a polyclonal antibody library specific for neglected proteins". *PLoS One* 2012; 7(4):e34395.
49. Novellino L, Rossi RL, Bonino F, Cavallone D, **Abrignani S**, Pagani M, Brunetto MR. "Circulating hepatitis B surface antigen particles carry hepatocellular

microRNAs". *PLoS One* 2012; 7(3), e31952.

50. Bottai D, Cigognini D, Nicora E, Moro M, Grimoldi MG, Adami R, **Abrignani S**, Marconi AM, Di Giulio AM, Gorio A. "Third trimester amniotic fluid cells with the capacity to develop neural phenotypes and with heterogeneity among sub-populations". *Restor Neurol Neurosci.* 2012;30(1):55-68. doi: 10.3233/RNN-2011-0620.
51. Bianco A, Reghellin V, Donnici L, Fenu S, Alvarez R, Baruffa C, Peri F, Pagani M, **Abrignani S**, Neddermann P, De Francesco R. "Metabolism of Phosphatidylinositol 4-Kinase III $\alpha$ -Dependent PI4P Is Subverted by HCV and Is Targeted by a 4-Anilino Quinazoline with Antiviral Activity". *PLoS Pathog* 2012; 8(3):e1002576.
52. Tonti E, Fedeli M, Napolitano A, Iannacone M, Von Andrian UH, Guidotti LG, **Abrignani S**, Casorati G, Dellabona P. "Follicular Helper NKT Cells Induce Limited B Cell Responses and Germinal Center Formation in the Absence of CD4+ T Cell Help" *J. Immunol.* 2012; 188(7):3217-22.

## 2011

53. Stamataki Z, Coates S, **Abrignani S**, Houghton M, McKeating JA. "Immunization of human volunteers with hepatitis C virus envelope glycoproteins elicits antibodies that cross-neutralize heterologous virus strains". *J Infect Dis.* 2011; 204(5):811-3.
54. Grifantini R, Pagani M, Pierleoni A, Grandi A, Parri M, Campagnoli S, Pileri P, Cattaneo D, Canidio E, Pontillo A, De Camilli E, Bresciani A, Marinoni F, Pedrazzoli E, Nogarotto R, **Abrignani S**, Viale G, Sarmientos P, Grandi G."A novel polyclonal antibody library for expression profiling of poorly characterized, membrane and secreted human proteins" *J. Proteomics* 2011; 75(2): 532-47.
55. (\*\*) Rossi RL., Rossetti G., Wenandy L., Curti S., Ripamonti A., Bonnal RJP., Sciarretta BR., Moro M., Crosti MC., Guarini P., Maglie S., Marabita F., Mascheroni D., Parente V., Comelli M., Trabucchi E., De Francesco R., Geginat J., **Abrignani S**, Pagani M. "Distinct microRNA signatures in human lymphocyte subsets and enforcement of T cell naïve state by miR-125b". *Nature Immunol.* 2011; 12, 796-803.
56. Marabita, F., Aghemo, A., De Nicola, S., Rumi, M. G., Cheroni, C., Scavelli, R., Crimi, M., Soffredini, R., **Abrignani, S.**, De Francesco, R., and Colombo, M. "Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection". *Hepatology* 2011. 54(4), 1127-1134.
57. Bosè F, Raeli L, Garutti C, Frigerio E, Cozzi A, Crimi M, Caprioli F, Scavelli R, Altomare G, Geginat J, **Abrignani S**, Reali E. "Dual role of anti-TNF therapy: enhancement of TCR-mediated T cell activation in peripheral blood and inhibition

of inflammation in target tissues ".*Clin Immunol.* 2011; 139(2):164-76.

## 2010

58. L. Rivino, P. Guarini, B. Häringer, S. Steinfelder, L. Lozza, E. Sugliano, A. Weick, D. Jarrossay, A. Kuehl, C. Loddenkemper, **S. Abrignani**, F. Sallusto, A. Lanzavecchia and J. Geginat "CCR6 is expressed on an IL-10 producing, auto-reactive memory T cell population with context-dependent regulatory function" *J. Exp. Med.* 2010; 207: 565-577.
59. Ray R, Meyer K, Banerjee A, Basu A, Coates S, **Abrignani S**, Houghton M, Frey SE, Belshe RB. "Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins". *J Infect Dis.* 2010; 202(6): 862-6.
60. Frey SE, Houghton M, Coates S, **Abrignani S**, Chien D, Rosa D, Pileri P, Ray R, Di Bisceglie AM, Rinella P, Hill H, Wolff MC, Schultze V, Han JH, Scharschmidt B, Belshe RB. "Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults". *Vaccine* 2010; 28(38): 6367-73.

## 2009

61. (\*\*) **Abrignani S**, Tonti E, Casorati G, Dellabona P. "B cell helper assays". *Methods Mol Biol.* 2009; 514: 15-26.
62. Tonti E, Galli G, Malzone C, **Abrignani S**, Casorati G, Dellabona P. "NKT-cell help to B lymphocytes can occur independently of cognate interaction". *Blood* 2009; 113(2): 370-6.

## 2008

63. (\*\*) Serra A, Nuti S, Tavarini S, Sammiceli C, Rosa D, Saletti G, Soldaini E, **Abrignani S**, Wack A. "Coligation of the hepatitis C virus receptor CD81 with CD28 primes naive T lymphocytes to acquire type 2 effector function". *J Immunol.* 2008; 181(1): 174-85.

## 2007

64. Stamataki Z, Coates S, Evans MJ, Winger M, Crawford K, Dong C, Fong YL, Chien D, **Abrignani S**, Balfe P, Rice CM, McKeating JA, Houghton M. "Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies". *Vaccine.* 2007; 25(45): 7773-84.
65. (\*\*) Galli G, Pittoni P, Tonti E, Malzone C, Uematsu Y, Tortoli M, Maione D, Volpini G, Finco O, Nuti S, Tavarini S, Dellabona P, Rappuoli R, Casorati G & **S Abrignani**. "Invariant NKT cells sustain specific B cell responses and memory". *PNAS.* 2007; 104: 3984-9.

## 2006

66. Brazzoli M, Crotta S, Bianchi A, Bagnoli F, Monaghan P, Wileman T, **Abrignani S** & M Merola. "Intracellular accumulation of hepatitis C virus proteins in a human hepatoma cell line". *J Hepatol.* 2006; 46: 53-59.
67. Vajdy M, Selby M, Medina-Selby A, Coit D, Hall J, Tandeske L, Chien D, Hu C, Rosa D, Singh M, Kazzaz J, Nguyen S, Coates S, Ng P, **Abrignani S**, Lin YL, Houghton M & O'Hagan DT. "Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses". *J Gen Virol.* 2006; 87: 2253-2262.
68. Crotta S, Ronconi V, Ulivieri C, Baldari CT, Valiente NM, **Abrignani S** & Wack A. "Cytoskeleton rearrangement induced by tetraspanin engagement modulates the activation of T and NK cells". *Eur J Immunol.* 2006; 36: 919-929.

## 2005

69. (\*\*) Rosa D, Saletti G, De Gregorio E, Zorat F, Comar C, D'Oro U, Nuti S, Houghton M, Barnaba V, Pozzato G & **S Abrignani**. "Activation of naive B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders". *PNAS.* 2005; 102: 18544-18549.
70. Kong WP, Xu L, Stadler K, Ulmer JB, **Abrignani S**, Rappuoli R & GJ Nabel. "Modulation of the immune response to the severe acute respiratory syndrome spike glycoprotein by gene-based and inactivated virus immunization". *J Virol.* 2005; 79: 13915-13923.
71. (\*\*) Houghton M & **S Abrignani**\*. "Prospects for a vaccine against the hepatitis C virus". *Nature* 2005; 436: 961-966.
72. Capo S, Nuti S, Scarselli M, Tavarini S, Montigiani S, Mori E, Finco O, **Abrignani S**, Grandi G & G Bensi. "Chlamydia pneumoniae genome sequence analysis and identification of HLA-A2-restricted CD8+ T cell epitopes recognized by infection-primed T cells". *Vaccine* 2005; 23: 5028-5037.
73. Mazzocca A, Cappadona Sciammetta S, Carloni V, Cosmi L, Annunziato F, Harada T, **Abrignani S** & M Pinzani. "Binding of hepatitis C virus envelope protein E2 to CD81 up-regulates matrix metalloproteinase-2 in human hepatic stellate cells". *J. Biol. Chem.* 2005; 280: 11329-11339.
74. (\*\*) Piccioli D, Tavarini S, Nuti S, Colombatto P, Brunetto M, Bonino F, Ciccorossi P, Zorat F, Pozzato G, Comar C, **Abrignani S** & A Wack. "Comparable functions of plasmacytoid and monocyte-derived dendritic cells in chronic Hepatitis C patients and healthy donors". *J. Hepatol.* 2005; 42: 61-67.
75. Brazzoli M, Helenius A, Fong SK, Houghton M, **Abrignani S** and M. Merola. "Folding and dimerization of hepatitis C virus E1 and E2 glycoproteins in stably transfected CHO cells". *Virology* 2005; 332: 438-453.

## 2004

76. (\*\*) Masciopinto F, Giovani C, Campagnoli S, Galli-Stampino L, Colombatto P, Brunetto M, Yen TS, Houghton M, Pileri P & **Abrignani S**. "Association of hepatitis C virus envelope proteins with exosomes". *Eur. J. Immunol.* 2004; 34: 2834-2842.
77. Song HC, Seo MY, Stadler K, Yoo BJ, Choo QL, Coates SR, Uematsu Y, Harada T, Greer CE, Polo JM, Pileri P, Eickmann M, Rappuoli R, **Abrignani S**, Houghton M & JH Han. "Synthesis and characterization of a native, oligomeric form of recombinant severe acute respiratory syndrome coronavirus spike glycoprotein". *J. Virol.* 2004; 78: 10328-10335.
78. De Lalla C, Galli G, Aldrighetti L, Romeo R, Mariani M, Monno A, Nuti S, Colombo M, Callea F, Porcelli SA, Panina-Bordignon P, **Abrignani S**, Casorati G & P Dellabona. "Production of profibrotic cytokines by invariant NKT cells characterizes cirrhosis progression in chronic viral hepatitis". *J. Immunol.* 2004; 173: 1417-1425.
79. Accapezzato D, Francavilla V, Paroli M, Casciaro M, Chircu LV, Cividini A, **Abrignani S**, Mondelli MU & V Barnaba. "Hepatic expansion of a virus-specific regulatory CD8(+) T cell population in chronic hepatitis C virus infection". *J. Clin. Invest.* 2004; 113: 963-972.

## 2003

80. Stadler K, Massignani V, Eickmann M, Becker S, **Abrignani S**, Klenk HD & R Rappuoli. "SARS--beginning to understand a new virus". *Nat. Rev. Microbiol.* 2003; 1: 209-218.
81. Eickmann M, Becker S, Klenk HD, Doerr HW, Stadler K, Censini S, Guidotti S, Massignani V, Scarselli M, Mora M, Donati C, Han JH, Song HC, **Abrignani S**, Covacci A & R Rappuoli. "Phylogeny of the SARS coronavirus". *Science.* 2003; 302: 1504-1505.
82. (\*\*) Galli G, Nuti S, Tavarini S, Galli Stampino L, De Lalla C, Casorati G, Dellabona P & **S Abrignani**. "Innate immune responses support adaptive immunity: NKT cells induce B cell activation". *Vaccine.* 2003; 21: S2/ 48-54.
83. (\*\*) Galli G, Nuti S, Tavarini S, Galli Stampino L, De Lalla C, Casorati G, Dellabona P & **S Abrignani**. "CD1d-Restricted Help To B Cells By Human Invariant NKT Lymphocytes". *J. Exp. Med.* 2003; 197: 1051-1057.
84. (\*\*) Soldaini E, Wack A, D'Oro U, Nuti S, Ulivieri C, Baldari CT & **S Abrignani**. "T cell costimulation by the hepatitis C virus envelope protein E2 binding to CD81 is mediated by Lck". *Eur. J. Immunol.* 2003; 33: 455-464.
85. Seo MY, **Abrignani S**, Houghton M & H Han. "Small interfering RNA-mediated inhibition of hepatitis C virus replication in the human hepatoma cell line Huh-7". *J. Virol.* 2003; 77: 810-812.

## 2002

86. Masciopinto F, Freer G, Burgio VL, Levy S, Galli-Stampino L, Bendinelli M, Houghton M, **Abrignani S** & Y Uematsu. "Expression of human CD81 in transgenic mice does not confer susceptibility to hepatitis C virus infection". *Virology*. 2002; 304: 187-196.
87. (\*\*) Crotta S, Stilla A, Wack A, D'Andrea A, Nuti S, D'Oro U, Mosca M, Filipponi F, Brunetto RM, Bonino F, **Abrignani S** & N Valiante. "Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein". *J Exp Med*. 2002; 195: 35-41.

## 2001

88. Falugi F, Petracca R, Mariani M, Luzzi E, Mancianti S, Carinci V, Melli ML, Finco O, Wack A, Di Tommaso A, De Magistris MT, Costantino P, Del Giudice G, **Abrignani S**, Rappuoli R & G Grandi. "Rationally designed strings of promiscuous CD4(+) T cell epitopes provide help to *Haemophilus influenzae* type b oligosaccharide: a model for new conjugate vaccines". *Eur J Immunol*. 2001; 31: 3816-38240.
89. (\*\*) Merola M, Brazzoli M, Cocchiarella F, Heile JM, Helenius A, Weiner AJ, Houghton M & **S Abrignani**. "Folding of hepatitis C virus E1 glycoprotein in a cell-free system". *J Virol*. 2001; 75: 11205-11217.
90. Burioni R, Bugli F, Mancini N, Rosa D, Di Campli C, Moroncini G, Manzin A, **Abrignani S**, Varaldo PE, Clementi M & G Fadda. "Nonneutralizing human antibody fragments against hepatitis C virus E2 glycoprotein modulate neutralization of binding activity of human recombinant Fabs". *Virology*. 2001; 288: 29-35, .
91. Agrati C, D'Offizi G, Narciso P, **Abrignani S**, Ippolito G, Colizzi V & F Poccia. "Vdelta1 T lymphocytes expressing a Th1 phenotype are the major gammadelta T cell subset infiltrating the liver of HCV-infected persons". *Mol.Med*. 2001. 7: 11-19.
92. Prezzi C, Casciaro MA, Francavilla V, Schiaffella E, Finocchi L, Chircu LV, Bruno G, Sette A, **Abrignani S** & V Barnaba. "Virus-specific CD8+ T cells with type 1 or type 2 cytokine profile are related to different disease activity in chronic hepatitis C virus infection". *Eur. J. Immunol*. 2001; 31: 894-906.
93. Kitadokoro K, Bordo D, Galli G, Petracca R, Falugi F, **Abrignani S**, Grandi G & M Bolognesi. "CD81 extracellular domain 3D structure: insight into the tetraspanin superfamily structural motifs". *EMBO J*. 2001; 15: 12-18.
94. (\*\*) Wack A, Soldaini E, Tseng CT, Nuti S, Klimpel GR & **S Abrignani**. "Binding of the hepatitis C virus envelope protein E2 to CD81 provides a co-stimulatory signal for human T cells". *Eur J Immunol*. 2001 ; 31:166-175.

## 2000

95. Hadlock KG, Lanford RE, Perkins S, Rowe J, Yang Q, Levy S, Pileri P, **Abrignani S** & SK Fong. "Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes". *J Virol.* 2000; 74: 10407-10416.
96. Allander T, Drakenberg K, Beyene A, Rosa D, **Abrignani S**, Houghton M, Widell A, Grillner L & MA Persson. "Recombinant human monoclonal antibodies against different conformational epitopes of the E2 envelope glycoprotein of hepatitis C virus that inhibit its interaction with CD81". *J Gen Virol.* 2000 ; 81: 2451-2459.
97. (\*\*) D'Andrea A, Goux D, De Lalla C, Koezuka Y, Montagna D, Moretta A, Dellabona P, Casorati G & **S Abrignani**. "Neonatal invariant Valpha24+ NKT lymphocytes are activated memory cells". *Eur J Immunol.* 2000 ; 30: 1544-1550.
98. (\*\*) Heile JM, Fong YL, Rosa D, Berger K, Saletti G, Campagnoli S, Bensi G, Capo S, Coates S, Crawford K, Dong C, Winger M, Baker G, Cousens L, Chien D, Ng P, Archangel P, Grandi G, Houghton M & **S Abrignani**. "Evaluation of hepatitis C virus glycoprotein E2 for vaccine design: an endoplasmic reticulum-retained recombinant protein is superior to secreted recombinant protein and DNA-based vaccine candidates". *J Virol.* 2000; 74: 6885-6892.
99. Petracca R, Falugi F, Galli G, Norais N, Rosa D, Campagnoli S, Burgio V, Di Stasio E, Giardina B, Houghton M, **Abrignani S** & G Grandi. "Structure-function analysis of hepatitis C virus envelope-CD81 binding". *J. of Virol.* 2000; 74: 4824-4830.
100. (\*\*) Valiante N, D'Andrea A, Crotta S, Lechner F, Klenerman O, Nuti S, Wack A & **S Abrignani**. "Life, activation and death of intrahepatic lymphocytes in chronic hepatitis C". *Immunol. Rev.* 2000; 174: 77-89.

## 1999

101. (\*\*) **Abrignani S**, Houghton M & HH Hsu "Perspectives for a vaccine against hepatitis C virus". *J Hepatol.* 1999, 31: 259-263.
102. Scognamiglio P, Accapezzato D, Casciaro MA, Cacciani A, Artini M, Bruno G, Chircu ML, Sidney J, Southwood S, **Abrignani S**, Sette A & V Barnaba. "Presence of effector CD8+ T cells in hepatitis C virus-exposed healthy seronegative donors". *J Immunol.* 1999; 162: 6681-6689.

## 1998

103. (\*\*) Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, Weiner AJ, Houghton M, Rosa D, Grandi G & **S Abrignani**. "Binding of hepatitis C Virus to CD81". *Science.* 1998; 282: 938-941.
104. (\*\*) Nuti S, Rosa D, Valiante NM, Saletti G, Caratozzolo M, Dellabona P, Barnaba V,



& **S Abrignani**. "Dynamics of intra-hepatic lymphocytes in chronic hepatitis C: enrichment for V $\alpha$ 24+ T-cells and rapid elimination of effector cells by apoptosis". *Eur. J. Imm.* 1998; 28: 3456-3467.

105. (\*\*) Ishii K, Rosa D, Watanabe Y, Katayama T, Harada H, Wyatt C, Kiyosawa K, Aizaki H, Matsuura Y, Houghton M, **Abrignani S** & T Miyamura. "High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C". *Hepatology*. 1998; 28: 1117-1120.
106. Habersetzer F, Fournillier A, Dubuisson J, Rosa D, **Abrignani S**, Wychowski C, Nakano I, Trepo C, Desgranges C, Inchauspe G. "Characterization of human monoclonal antibodies specific to the hepatitis C virus glycoprotein E2 with in vitro binding neutralization properties". *Virology*. 1998; 249: 32-41.
107. Burioni R, Plaisant P, Manzin A, Rosa D, Delli Carri V, Bugli F, Solfrosi L, **Abrignani S**, Varaldo PE, Fadda G & M Clementi. "Dissection of human humoral immune response against hepatitis C virus E2 glycoprotein by repertoire cloning and generation of recombinant Fab fragments". *Hepatology*. 1998; 28: 810-814.
108. **Abrignani S**. "Antigen-independent activation of resting T-cells in the liver of patients with chronic hepatitis". *Dev. Biol. Stand.* 1998; 92: 191-194.
109. Grifantini R, Finco O, Bartolini E, Draghi M, Del Giudice G, Kochen C, Thomas A, **Abrignani S** & G Grandi. "Multi-plasmid DNA vaccination avoids antigenic competition and enhances immunogenicity of a poorly immunogenic plasmid". *Eur. J. Imm.* 1998; 28: 1225-1232.

## 1997

110. (\*\*) **Abrignani S**. "Bystander activation by cytokines of intrahepatic T cells in chronic viral hepatitis". *Seminars in Liver Disease* 1997; 17: 319-322.
111. (\*\*) **Abrignani S**. "Immune responses throughout HCV infection: HCV from the immune system point of view". Springer Seminars in *Immunopathology*. 1997; 19: 47-56.
112. (\*\*) Finco O, Nuti S, Mangiavacchi L, Aiuti A, Forte P, Fantoni A, van der Putten H & **S Abrignani**. "Induction of CD4+ T-cell depletion in mice doubly transgenic for HIV-gp120 and human CD4". *Eur. J. Imm.* 1997; 27: 1319-1324.

## 1996

113. (\*\*) Rosa D, Campagnoli S, Moretto C, Guenzi E, Cousens L, Chin M, Dong C, Weiner A, Lau J, Choo Q, Chien D, Pileri P, Houghton M & **S Abrignani**. "A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein-E2 binding to target cells". *PNAS* 1996; 93: 1759-1763.

114. Di Tommaso A, Saletti G, Pizza M, Rappuoli R, Dougan G, **Abrignani S**, Douce G & M De Magistris. "Induction of antigen-specific antibodies in vaginal secretions using a non-toxic mutant of LT as a mucosal adjuvant". *Infect. Immun.* 1996; 64: 974-979.

### 1995

115. (\*\*) Unutmaz D, Baldoni F & **S Abrignani**. "Human naive T cells activated by cytokines differentiate into a split phenotype with functional features intermediate between naive and memory cells". *Int. Immunol.* 1995; 9: 1417-1424.

116. **Abrignani S**. "Cellular immune reactions against hepatitis C core in chronic hepatitis C". *Gastroenterology* 1995; 108: 1957-1958.

117. Di Tommaso A, Xiang Z, Bugnoli M, Figura N, Bayeli P, Rappuoli R, **Abrignani S** & MT De Magistris. "Helicobacter Pylori specific CD4+ T cell clones from peripheral blood and gastric biopsies". *Infect. Immun.* 1995; 63:1102-1106.

### 1994

118. (\*\*) Unutmaz D, Pileri P & **S Abrignani**. "Antigen-independent activation of naive and memory resting T cells by a cytokine combination". *J. Exp. Med.* 1994; 180: 1159-1164.

119. (\*\*) Di Tommaso A, De Magistris MT, Bugnoli M, Marsili I, Rappuoli R & **S Abrignani**. "Formaldehyde-treatment of proteins can constrain presentation to T-cells by limiting antigen processing". *Infect. Immun.* 1994; 62: 1830-1834.

### 1993

120. (\*\*) Minutello M, Pileri P, Unutmaz D, Censini S, Kuo G, Houghton M, Bonino F, Brunetto M & **S Abrignani**. "Compartmentalization of T-lymphocytes to the site of disease: Intrahepatic CD4+ T-cells specific for the protein NS4 of hepatitis C virus in patients with chronic hepatitis". *J. Exp. Med.* 1993; 178: 17-25.

121. (\*\*) Botarelli P, Brunetto M, Minutello M, Calvo P, Unutmaz D, Weiner AJ, Choo QL, Shuster J, Kuo G, Bonino F, Houghton M & **S Abrignani**. "T lymphocyte response to hepatitis C virus in different clinical courses of infection". *Gastroenterology* 1993; 104: 580-587.

### 1992

122. (\*\*) Minutello M, Unutmaz D, Brunetto M, Kuo G, Bonino F, Houghton M & **S Abrignani**. "T-cell response to HCV in peripheral blood and liver and its correlation with protection and pathogenicity". *J. Hepatol.* 1992; 17, S1: 5-6.

### 1991

123. (\*\*) Botarelli P, Houlden B A, Haigwood NL, Servis K, Montagna D & **S Abrignani**. "N-glycosylation of HIV-gp120 may constrain recognition by T lymphocytes". *J Immunol.* 1991 147(9):3128-32.

## 1990

124. (\*\*) **Abrignani S**, Montagna D, Jeannet M, Wintsch J, Haigwood NL, Shuster JR, Steimer KS, Cruchaud A & T Staehelin. "Priming of CD4<sup>+</sup> T cells specific for conserved regions of HIV-gp120 in humans immunized with a recombinant envelope protein". *Proc Natl Acad Sci USA*. 1990 87(16):6136-40.

## 1988

125. (\*\*) Lanzavecchia A, Roosnek E, Gregory T, Berman P & **S Abrignani**. "T cells can present antigens such as HIV gp120 targeted to their own surface molecules". *Nature*. 1988 334(6182):530-2.
126. Lanzavecchia A, **Abrignani S**, Scheidegger D, Obrist R, Doerken B & G Moldenhauer. "Antibodies as antigen: the use of monoclonal antibodies to focus human T cells against selected targets". *J Exp Med*. 1988; 167(2):345-52.

**Brevetti sottomessi e brevetti rilasciati**

Titolo brevetto	Anno di priorità	N° domanda di brevetto	Nation	Anno di Rilascio	N° di brevetto
Cancer treatment	2016	PCT/EP/2017/061642	Fase PCT		
Biomarkers for autoimmune liver diseases and uses thereof	2011	14125128	USA		
		2837522	CANADA		
		2012269083	AUSTRALIA	2016	2012269083
		127336154	EUROPA	2016	2721413
Prion chimeras and uses thereof	2003	2003279088	AUSTRALIA		
Eliciting HCV specific antibodies	1999	US12/001,920	USA		
Intracellular production of hepatitis C E1 and E2 truncated polypeptides	1997	10371040	USA	2008	US7429385 B2
Hepatitis C Receptor Protein Cd81	1997	EP1021534 A1	EUROPA		
		WO1999018198A1	USA	2006	US7097987 B2
Hepatitis C virus E2 binding protein	1995	11/372,935	USA	2008	US7320875 B2
T cell activation by cytokine combinations	1994	1995927917	EUROPA	2009	EP0772677 B1
		JP2006312640 A	JAPAN		
		2197801	CANADA		
		US2005/0281793 A1	USA		
Assay To Detect HCV Receptor Binding	1994	95927918.3	EU	2008	EP0723665 B2
		2174212 A	CANADA	2003	2174212 C
		DE1995632498	DENMARK	2004	69532498 D1
		1995/031894 A	AUSTRALIA		
		US11/784,521	USA		
		2004004113 A	JAPAN	2008	JP4117230 B2

**Finanziamenti competitivi degli ultimi 10 anni**

Titolo Progetto	Fonte del Finanziamento	Mia quota (EUR)	Periodo	Ruolo PI
"Insights into the evolving heterogeneity of metastatic colorectal cancer: from mechanisms to therapies"	AIRC 5x1000	2.500.000	2018-2025	Partecipante
"Immunity in Cancer Spreading and Metastasis"	AIRC 5x1000	879.000	2018-2025	Partecipante
"EPIGEN" - Physiopathological role of non-coding RNAs in the epigenetic regulation of CD4+ human T lymphocytes	Ministero dell'Istruzione dell'Università e Ricerca (MIUR) e CNR	300.000	2013-2017	Coordinatore

Cluster Tecnologico Nazionale ALISEI: Progetto Medintech CTN01_00177_962865: "Cutting-edge technologies to increase safety and efficacy of drugs and vaccines"	Ministero dell'Istruzione e dell'Università e della Ricerca (MIUR)	844.000	2014-2017	Resp. Scientifico
"Serum microRNAs released by human CD4+ T cell subsets as biomarkers of vaccine efficacy and adverse events"	Merieux Research Grant	100.000	2014-2016	Resp. Scientifico
Grant n. 269022: i-MIRNOME - Lymphocyte microRNAs in health and disease: Understanding lymphocyte functions through the identification of microRNA target genes and exploiting serum microRNA signatures to monitor immune responses	ERC Advanced Grant	2.496.000	2011-2016	Resp. Scientifico
Grant n. RF-2011-02348466: "GENomwide association study to Evaluate genetic risk factors for cerebral sinus-venous thromboSIS (GENESIS Study)	Ministero della Salute	171.609	2016-2017	Co-Resp. Scientifico
Grant n. 2009-3603: "Improving vaccines for the developing world by means of new adjuvants potentiating effector and memory responses"	Fondazione Cariplo	489.919	2011-2014	Coordinatore
Grant n. RBAP10TPXK_002: "Eventi cellulari e molecolari nella patogenesi delle infezioni croniche da HBV o HCV"	Ministero dell'Istruzione dell'Università e Ricerca (MIUR)	343.300	2011-2015	Co-Resp. Scientifico
microRNA atlas in peripheral blood lymphocytes	Ministero della Salute e Regione Lombardia	2.000.000	2012-2013	Resp. Scientifico
Hepacivac: LSH-2005-1.2.4-2 # 037435	Unione Europea - 6PQ	1.200.000	2005-2011	Coordinatore

Il sottoscritto è a conoscenza che, ai sensi dell'art. 26 della legge 15/68, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali.  
Inoltre, il sottoscritto autorizza al trattamento dei dati personali, secondo quanto previsto dalla Legge 196/03.

SERGIO ABRIGNANI

Milano, 28 giugno 2018